Status:
UNKNOWN
The Effects of Acetylcysteine on Alleviating Damage of Oxidative Stress in Hemodialysis Patients
Lead Sponsor:
Far Eastern Memorial Hospital
Conditions:
Anemia
Atherosclerosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The aim of this study is to explore and identify the effects of acetylcysteine, a common mucolytic with anti-oxidant property, on alleviating the damage caused by increased oxidative stress in hemodia...
Detailed Description
Oxidative stress in patients with renal failure is higher than in healthy controls. Once undergoing hemodialysis (HD) therapy, patients with end-stage renal disease even have more oxidative stress. Re...
Eligibility Criteria
Inclusion
- On HD thrice a week at our HD unit for more than three months
- Informed consent
- The dose of EPO and iron supplement is stationary in the previous one month
- No taking acetylcysteine in previous one month
- No using vitamin E-bonded dialysis membrane
Exclusion
- Severe liver disease (AST or ALT \>40 IU/L), proven malignancy, and severe cardiovascular disease (proved by cardiac catheter or echography examination)
- Active infection or hospitalization in previous one month
- Clinically significant bleeding episode in previous one month
- Taking vitamin C, vitamin E or other known antioxidants.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00247507
Start Date
September 1 2005
End Date
December 1 2005
Last Update
October 18 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Far Eastern Memorial Hospital
Pan-Chiao, Taipei, Taiwan, 220